Cargando…

Broken drug markets in infectious diseases: Opportunities outside the private sector?

A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that pub...

Descripción completa

Detalles Bibliográficos
Autores principales: Alpern, Jonathan D., Dunlop, Stephen J., Stauffer, William M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459471/
https://www.ncbi.nlm.nih.gov/pubmed/30973876
http://dx.doi.org/10.1371/journal.pntd.0007190
_version_ 1783410182804471808
author Alpern, Jonathan D.
Dunlop, Stephen J.
Stauffer, William M.
author_facet Alpern, Jonathan D.
Dunlop, Stephen J.
Stauffer, William M.
author_sort Alpern, Jonathan D.
collection PubMed
description A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution.
format Online
Article
Text
id pubmed-6459471
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64594712019-05-03 Broken drug markets in infectious diseases: Opportunities outside the private sector? Alpern, Jonathan D. Dunlop, Stephen J. Stauffer, William M. PLoS Negl Trop Dis Viewpoints A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution. Public Library of Science 2019-04-11 /pmc/articles/PMC6459471/ /pubmed/30973876 http://dx.doi.org/10.1371/journal.pntd.0007190 Text en © 2019 Alpern et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Viewpoints
Alpern, Jonathan D.
Dunlop, Stephen J.
Stauffer, William M.
Broken drug markets in infectious diseases: Opportunities outside the private sector?
title Broken drug markets in infectious diseases: Opportunities outside the private sector?
title_full Broken drug markets in infectious diseases: Opportunities outside the private sector?
title_fullStr Broken drug markets in infectious diseases: Opportunities outside the private sector?
title_full_unstemmed Broken drug markets in infectious diseases: Opportunities outside the private sector?
title_short Broken drug markets in infectious diseases: Opportunities outside the private sector?
title_sort broken drug markets in infectious diseases: opportunities outside the private sector?
topic Viewpoints
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459471/
https://www.ncbi.nlm.nih.gov/pubmed/30973876
http://dx.doi.org/10.1371/journal.pntd.0007190
work_keys_str_mv AT alpernjonathand brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector
AT dunlopstephenj brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector
AT staufferwilliamm brokendrugmarketsininfectiousdiseasesopportunitiesoutsidetheprivatesector